EMTC-M Stock Overview
An investment holding company, engages in the research, development, production, and marketing of therapeutic medical systems in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Elbit Medical Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.17 |
| 52 Week High | ₪0.26 |
| 52 Week Low | ₪0.12 |
| Beta | 0.21 |
| 1 Month Change | -21.88% |
| 3 Month Change | 17.45% |
| 1 Year Change | 1.16% |
| 3 Year Change | -87.51% |
| 5 Year Change | -84.49% |
| Change since IPO | -94.39% |
Recent News & Updates
Shareholder Returns
| EMTC-M | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | -4.4% | -2.2% | 2.6% |
| 1Y | 1.2% | 7.6% | 25.9% |
Return vs Industry: EMTC-M underperformed the IL Medical Equipment industry which returned 7.6% over the past year.
Return vs Market: EMTC-M underperformed the IL Market which returned 25.9% over the past year.
Price Volatility
| EMTC-M volatility | |
|---|---|
| EMTC-M Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.6% |
Stable Share Price: EMTC-M's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: EMTC-M's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of IL stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 486 | Ron Hadassi | n/a |
Elbit Medical Technologies Ltd, an investment holding company, engages in the research, development, production, and marketing of therapeutic medical systems in the United States, Europe, and internationally. The company is developing a magnetic resonance imaging guided focused ultrasound treatment equipment to address various oncology and gynecology indications, as well as neurological disorders and tumors. It is also involved in the study and development of medical products based on stem cells originating primarily from the umbilical cord blood that are used for bone marrow transplants in the patients of leukemia or cancer of lymph nodes, non-malignant blood diseases, and metabolic genetic disorders.
Elbit Medical Technologies Ltd Fundamentals Summary
| EMTC-M fundamental statistics | |
|---|---|
| Market cap | ₪15.88m |
| Earnings (TTM) | ₪3.06m |
| Revenue (TTM) | ₪4.92m |
5.2x
P/E Ratio3.2x
P/S RatioIs EMTC-M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMTC-M income statement (TTM) | |
|---|---|
| Revenue | US$1.33m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.33m |
| Other Expenses | US$503.00k |
| Earnings | US$827.00k |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0091 |
| Gross Margin | 100.00% |
| Net Profit Margin | 62.18% |
| Debt/Equity Ratio | 0% |
How did EMTC-M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 01:05 |
| End of Day Share Price | 2025/04/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elbit Medical Technologies Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.